Heart transplant complications: Difference between revisions
Neil.m.young (talk | contribs) (Text replacement - "==Diagnosis==" to "==Evaluation==") |
ClaireLewis (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
*Indications: end-stage [[heart failure]] refractory to standard medical/surgical treatment | |||
*Transplanted heart is denervated | |||
**Resting rate between 90-100 bpm | |||
**Response to exertion/stress is blunted by lack of central mediated tachycardia, though can still respond to circulating catecholamines | |||
{{Immunosuppressant medication complications}} | {{Immunosuppressant medication complications}} | ||
==Clinical Features== | ==Clinical Features== | ||
===Rejection=== | |||
*Patients monitored with surveillance biopsies regularly | |||
*Spectrum of presentations, anywhere asymptomatic to in extremis | |||
**Features include dysrythmias, decreased exercise tolerance, and infection may be clues | |||
===Infection=== | |||
**Increased risk of opportunistic/severe infections | |||
**Fever and other classic features may be absent due to immunopression | |||
===Signs/Symptoms of Congestive Heart Failure=== | |||
*Due to various etiologies | |||
*MI may present only with CHF symptoms | |||
===Medication Adverse Effects=== | |||
*Prednisone | |||
**Hyperglycemia, psychiatric symptoms, poor wound healing, edema, hypertension | |||
*Tacrolimus, cyclosporine | |||
**Neurotoxicity, tremor, hyperkalemia, nephrotoxicity, hypertension, hyperglycemia, gout | |||
*Mycophenolate | |||
**Cytopenias, GI distress | |||
*Azathioprine | |||
**Cytopenias, pancreatitis, hepatitis | |||
===[[Myocardial ischemia]]/CAD=== | |||
*Pediatric recipients in particular at risk for graft CAD | |||
*Due to denervation, transplant patients with ’’’NOT’’’ have pain with [[ACS]] | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
==Evaluation== | ==Evaluation== | ||
''Workup dependent on presentation, considerations include:'' | |||
==Management== | *CBC, BMP, Mg/Phos | ||
*Low threshhold for infectious workup, including viral/fungal studies | |||
*Tacrolimus, cyclosporine levels | |||
*[[EKG]] | |||
**Patient’s native sinus node often preserved | |||
***→ two P waves on EKG | |||
***donor P wave will be in 1:1 relationship with QRS, native P wave has independent rhythm | |||
*[[CXR | |||
**May]] have relative "cardiomegaly" if donor was much larger than recipient | |||
*CT Chest | |||
**May be required to diagnose PE, hypoxemia, pneumonia | |||
*Echo | |||
**Consider if signs/symptoms of heart failure | |||
==Management Considerations== | |||
*Consult/discuss with transplant team | |||
*Rejection | |||
**Diagnosed by biopsy | |||
**Do not treat if stable, as steroids will muddy biopsy results | |||
**[[Methylprednisolone]] 1g IV if in extremis | |||
*Dysrythmias | |||
**[[Bradycardia]] will ‘’’NOT’’’ respond to atropine due to denervation | |||
***transplant patients with symptomatic bradycardia may respond to isoproterenol 1 μg/min, titrated slowly to max 4 μg/min | |||
**Transplant patients may be overly sensitive to adverse effects from [[adenosine]] | |||
**Sinus node dysfunction usually requires pacemaker placement | |||
*See [[Immunocompromised antibiotics]] | |||
==Disposition== | ==Disposition== | ||
Revision as of 18:37, 25 September 2016
Background
- Indications: end-stage heart failure refractory to standard medical/surgical treatment
- Transplanted heart is denervated
- Resting rate between 90-100 bpm
- Response to exertion/stress is blunted by lack of central mediated tachycardia, though can still respond to circulating catecholamines
Immunosuppressant Medications
- Balance between immune suppression, rejection and susceptibility to infection
- Typical regimen includes: calcineurin inhibitor + antimetabolite + steroid
- Calcineurin inhibitor
- Steroids
- +/- Antimetabolite
Clinical Features
Rejection
- Patients monitored with surveillance biopsies regularly
- Spectrum of presentations, anywhere asymptomatic to in extremis
- Features include dysrythmias, decreased exercise tolerance, and infection may be clues
Infection
- Increased risk of opportunistic/severe infections
- Fever and other classic features may be absent due to immunopression
Signs/Symptoms of Congestive Heart Failure
- Due to various etiologies
- MI may present only with CHF symptoms
Medication Adverse Effects
- Prednisone
- Hyperglycemia, psychiatric symptoms, poor wound healing, edema, hypertension
- Tacrolimus, cyclosporine
- Neurotoxicity, tremor, hyperkalemia, nephrotoxicity, hypertension, hyperglycemia, gout
- Mycophenolate
- Cytopenias, GI distress
- Azathioprine
- Cytopenias, pancreatitis, hepatitis
Myocardial ischemia/CAD
- Pediatric recipients in particular at risk for graft CAD
- Due to denervation, transplant patients with ’’’NOT’’’ have pain with ACS
Differential Diagnosis
Evaluation
Workup dependent on presentation, considerations include:
- CBC, BMP, Mg/Phos
- Low threshhold for infectious workup, including viral/fungal studies
- Tacrolimus, cyclosporine levels
- EKG
- Patient’s native sinus node often preserved
- → two P waves on EKG
- donor P wave will be in 1:1 relationship with QRS, native P wave has independent rhythm
- Patient’s native sinus node often preserved
- [[CXR
- May]] have relative "cardiomegaly" if donor was much larger than recipient
- CT Chest
- May be required to diagnose PE, hypoxemia, pneumonia
- Echo
- Consider if signs/symptoms of heart failure
Management Considerations
- Consult/discuss with transplant team
- Rejection
- Diagnosed by biopsy
- Do not treat if stable, as steroids will muddy biopsy results
- Methylprednisolone 1g IV if in extremis
- Dysrythmias
- Bradycardia will ‘’’NOT’’’ respond to atropine due to denervation
- transplant patients with symptomatic bradycardia may respond to isoproterenol 1 μg/min, titrated slowly to max 4 μg/min
- Transplant patients may be overly sensitive to adverse effects from adenosine
- Sinus node dysfunction usually requires pacemaker placement
- Bradycardia will ‘’’NOT’’’ respond to atropine due to denervation
- See Immunocompromised antibiotics
